Back to top

Image: Bigstock

What's in Store for Kulicke and Soffa (KLIC) in Q2 Earnings?

Read MoreHide Full Article

Kulicke and Soffa (KLIC - Free Report) is set to release second-quarter fiscal 2021 results on May 6.

The company recently raised its guidance for the to-be-reported quarter and now expects revenues to be roughly $340 million. Moreover, adjusted earnings are expected to be roughly $1.20 per share.

The Zacks Consensus Estimate is currently pegged at $1.20 per share, which has moved 32% north over the past 30 days. The company had reported earnings of 22 cents per share in the year-ago quarter.

Moreover, the consensus mark for the top line is currently pegged at $340 million, implying 125.6% growth from the figure reported in the year-ago quarter.

Markedly, Kulicke and Soffa’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, missing the same in the remaining one, the earnings surprise being 32.5%.

Kulicke and Soffa Industries, Inc. Price and EPS Surprise

Factors to Note

Kulicke and Soffa’s second-quarter 2021 results are expected to have benefited from strong demand for its solutions in the semiconductor, automotive and LED end-markets.

Moreover, solid adoption of semiconductor offerings supporting high-density assembly and advanced LED solutions supporting emerging mini-LED capable displays are key catalysts.

Further, an improving supply chain is expected to have benefited top-line growth in the to-be-reported quarter.

Key Q2 Developments

During fiscal second quarter, Kulicke and Soffa acquired a 100% equity stake in Laser-Enabled Advanced Placement technology provider Uniqarta. The deal strengthened Kulicke and Soffa’s mini and micro LED technology portfolio.

What Our Model Indicates

Per the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.

Kulicke and Soffa has an Earnings ESP of 0.00% and a Zacks Rank #1. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Stocks to Consider

Here are a few other companies worth considering as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases:

CDW Corporation (CDW - Free Report) has an Earnings ESP of +0.51% and is Zacks #2 Ranked. You can see the complete list of today’s Zacks #1 Rank stocks here.

Fair Isaac (FICO - Free Report) has an Earnings ESP of +15.94% and is #2 Ranked.

Waters Corporation (WAT - Free Report) has an Earnings ESP of +2.94% and a Zacks Rank #2.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>